Himension Capital Singapore PTE. LTD. Acquires 14,383 Shares of Tempus AI, Inc. $TEM

Himension Capital Singapore PTE. LTD. increased its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 42.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,114 shares of the company’s stock after purchasing an additional 14,383 shares during the quarter. Himension Capital Singapore PTE. LTD.’s holdings in Tempus AI were worth $2,176,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. JPL Wealth Management LLC purchased a new stake in Tempus AI during the third quarter valued at about $26,000. Los Angeles Capital Management LLC bought a new position in shares of Tempus AI during the fourth quarter valued at about $27,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Tempus AI in the third quarter worth about $38,000. Whittier Trust Co. lifted its stake in shares of Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after acquiring an additional 570 shares during the last quarter. Finally, Lodestone Wealth Management LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at about $42,000. 24.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TEM has been the topic of several recent research reports. BTIG Research restated a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research report on Monday, June 1st. Lake Street Capital downgraded Tempus AI to a “hold” rating in a research report on Monday. Freedom Capital raised Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. TD Cowen restated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Finally, Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Nine investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $68.92.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: The Personalis acquisition could deepen Tempus AI’s position in precision oncology and expand its addressable market in cancer monitoring. Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring
• Positive Sentiment: Needham reaffirmed a Buy rating and set a $75 price target, suggesting analysts still see meaningful upside despite the transaction-related selloff. Needham on Tempus AI Inc (TEM): ‘Buyers of any weakness related to the transaction’
• Neutral Sentiment: Tempus said it signed a definitive merger agreement to acquire Personalis, giving investors more clarity on the structure and terms of the deal. Tempus AI Announces Merger Agreement to Acquire Personalis
• Negative Sentiment: The market is reacting cautiously to the size of the deal, likely due to dilution, integration risk, and the fact that both stocks fell after the announcement. Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Insider Activity at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 8,703 shares of Tempus AI stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the sale, the executive vice president directly owned 128,215 shares of the company’s stock, valued at approximately $5,650,435.05. The trade was a 6.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $46.70, for a total value of $7,763,875.00. Following the transaction, the chief executive officer owned 8,808,533 shares in the company, valued at $411,358,491.10. This trade represents a 1.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 616,043 shares of company stock valued at $31,748,593 in the last three months. Corporate insiders own 24.26% of the company’s stock.

Tempus AI Stock Performance

NASDAQ:TEM opened at $48.98 on Wednesday. The stock has a market cap of $8.80 billion, a P/E ratio of -28.48 and a beta of 3.46. The firm’s fifty day simple moving average is $51.64 and its 200 day simple moving average is $53.84. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. During the same period in the prior year, the business earned ($0.24) EPS. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. As a group, research analysts predict that Tempus AI, Inc. will post -1.35 EPS for the current year.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.